Investigation of P53 Codon 72 Polymorphism in Patients with Nonmelanoma Skin Cancers in Isfahan

Document Type : Original Article (s)

Authors

1 Associate Professor, Department of Anatomical Sciences, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.

2 Student of Medical, Student Research Committee, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

3 Associate Professor, Department of Pathology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

4 Epidemiologist, Department of Epidemiology and Biostatistics, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: The P53 tumor suppressor gene plays important roles in genomic stability. G–to-C at codon 72 in the P53 gene has been associated with increased risk for lung, oral, prostate, breast, colorectal cancers and may be a marker for risk of skin cancer. This project studied the effect of P53 polymorphism on risk of nonmelanoma skin cancers (Squamous and basal cell carcinoma).Methods: This case–control study undertook for study of twenty basal cell carcinoma (BCC), twenty squamous cell carcinoma (SCC) and twenty specimens as controls for each cancer specimen in the city of Isfahan, Iran. Different P53 codon 72 genotypes were identified using polymerase chain reaction.Finding: In control samples, the frequency of Arg/Arg genotype showed 25% and in BCC specimens showed 60%. The differences in this genotype group between the cases and controls were statistically significant (P = 0.048). The differences in the frequency of heterozygot Arg/Pro and also in the frequency of Pro/Pro genotype between the cases and controls were not statistically significant. OR = 4.5 in BCC cases show that the risk for this disease in persons who have Arg/Arg genotype is about 4.5 times more than normal people. The results of χ2 test showed that in this study there is not statistically significant differences between the SCC specimens and controls for frequency of different genotypes.Conclusion: The present study indicate that P53 codon 72 polymorphism is a genetic predisposing factor for risk of nonmelanoma skin cancers (of BCC type) in Isfahan. However, further studies are needed in order to elucidate the role of P53 codon 72 polymorphism in skin cancer development. 

Keywords

References

  1. Diepgen TL, Mahler V. The epidemiology of skin cancer. Br J Dermatol 2002; 146 Suppl 61: 1-6.
  2. Housman TS, Feldman SR, Williford PM, Fleischer AB, Jr., Goldman ND, Acostamadiedo JM, et al. Skin cancer is among the most costly of all cancers to treat for the Medicare population. J Am Acad Dermatol 2003; 48(3): 425-9.
  3. Wheless L, Black J, Alberg AJ. Nonmelanoma skin cancer and the risk of second primary cancers: a systematic review. Cancer Epidemiol Biomarkers Prev. 2010; 19(7): 1686-95
  4. Albert MR, Weinstock MA. Keratinocyte carcinoma. CA Cancer J Clin 2003; 53(5): 292-302.
  5. Tilli CM, Van Steensel MA, Krekels GA, Neumann HA, Ramaekers FC. Molecular aetiology and pathogenesis of basal cell carcinoma. Br J Dermatol 2005; 152(6): 1108-24.
  6. Becker WM, Kleinsmith LJ, Hardin J. The World of the Cell. 6th ed. Sanfrancisco: Benjamin Cummings; 2005. p. 783-5.
  7. Srivastava S, Zou ZQ, Pirollo K, Blattner W, Chang EH. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 1990; 348(6303): 747-9.
  8. Hofseth LJ, Hussain SP, Harris CC. p53: 25 years after its discovery. Trends Pharmacol Sci 2004; 25(4): 177-81.
  9. Wang SP, Wang WL, Chang YL, Wu CT, Chao YC, Kao SH, et al. p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug. Nat Cell Biol 2009; 11(6): 694-704.
  10. Cao Z, Song JH, Park YK, Maeng EJ, Nam SW, Lee JY, et al. The p53 codon 72 polymorphism and susceptibility to colorectal cancer in Korean patients. Neoplasma 2009; 56(2): 114-8.
  11. Zhang J, Zhuo WL, Zheng Y, Zhang YS. Polymorphisms of TP53 codon 72 with prostate carcinoma risk: a meta-analysis. Med Oncol 2010; 27(2): 540-6.
  12. Aoki MN, da Silva do Amaral Herrera AC, Amarante MK, do Val Carneiro JL, Fungaro MH, Watanabe MA. CCR5 and p53 codon 72 gene polymorphisms: implications in breast cancer development. Int J Mol Med 2009; 23(3): 429-35.
  13. Zemleduch T, Lianeri M, Rydzanicz M, Gajecka M, Szyfter K, Jagodzinski PP. Contribution of polymorphism in codon 72 of TP53 gene to laryngeal cancer in Polish patients. Oral Oncol 2009; 45(8): 683-6.
  14. Mahasneh AA, Abdel-Hafiz SS. Polymorphism of p53 gene in Jordanian population and possible associations with breast cancer and lung adenocarcinoma. Saudi Med J 2004; 25(11): 1568-73.
  15. Gomez-Lazaro M, Fernandez-Gomez FJ, Jordan J. p53: twenty five years understanding the mechanism of genome protection. J Physiol Biochem 2004; 60(4): 287-307.
  16. Papadakis EN, Dokianakis DN, Spandidos DA. p53 codon 72 polymorphism as a risk factor in the development of breast cancer. Mol Cell Biol Res Commun 2000; 3(6): 389-92.
  17. Wang YC, Chen CY, Chen SK, Chang YY, Lin P. p53 codon 72 polymorphism in Taiwanese lung cancer patients: association with lung cancer susceptibility and prognosis. Clin Cancer Res 1999; 5(1): 129-34.
  18. Pezeshki A, Sari-Aslani F, Ghaderi A, Doroudchi M. p53 codon 72 polymorphism in basal cell carcinoma of the skin. Pathol Oncol Res 2006; 12(1): 29-33.
  19. de Oliveira WR, Rady PL, Grady J, Hughes TK, Neto CF, Rivitti EA, et al. Association of p53 arginine polymorphism with skin cancer. Int J Dermatol 2004; 43(7): 489-93.
  20. Bastiaens MT, Struyk L, Tjong AHS, Gruis N, ter Huurne J, Westendorp RG, et al. Cutaneous squamous cell carcinoma and p53 codon 72 polymorphism: a need for screening? Mol Carcinog 2001; 30(1): 56-61.
Journal of Isfahan Medical School
Volume 29, Issue 141 - Serial Number 141
May and June 2011
Pages 679-685

Files

History

  • Receive Date: 06 July 2011
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics